All products have special prices for bulk purchase, please contact for more details if required.

Cat. No.: TFrCas9-500 (for 500pmol)

Cat. No.: TFrCas9-2500 (for 2500pmol)

Description

TREX2‑FrCas9 is an engineered fusion protein combining FrCas9 with Three‑prime Repair Exonuclease 2 (TREX2), a 3'→5' exonuclease that profoundly alters the DNA repair outcomes of CRISPR‑Cas9 editing. TREX2 progressively digests nucleotides from DNA double‑strand break (DSB) ends, and when fused to FrCas9, it generates substantially larger deletions at the cleavage site.

In conventional CRISPR‑Cas9 editing, DSBs are repaired primarily through the non‑homologous end joining (NHEJ) pathway, typically producing small insertions or deletions (most <10 bp). Such small indels may be insufficient to fully disrupt gene function, especially for non‑coding RNAs, regulatory elements, or structured protein domains. TREX2‑FrCas9 overcomes this limitation: once FrCas9 introduces a DSB, the fused TREX2 immediately performs 3'→5' exonucleolytic digestion, widening the break and forcing NHEJ repair to generate much larger deletions—often spanning hundreds of base pairs.

This capability makes TREX2‑FrCas9 particularly valuable for applications requiring complete gene disruption, such as microRNA knockout, long non‑coding RNA inactivation, or removal of entire functional protein domains. For example, mature microRNAs are only 20–22 bp long, and small indels from standard Cas9 often fail to disrupt their hairpin structure or processing sites. In contrast, the large deletions produced by TREX2‑FrCas9 ensure full loss of function. Compared with traditional dual‑sgRNA strategies used to induce large deletions, TREX2‑FrCas9 achieves similar outcomes with a single sgRNA, simplifying experimental design and reducing off‑target risk.